Paydirt
HOWL
Ticker

Werewolf Therapeutics, Inc.

HOWL · Healthcare · Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's imm…

Werewolf Therapeutics, Inc. (HOWL), in the Healthcare sector, has 5 disclosed filings on Paydirt over the trailing twelve months from 3 corporate insiders: 0 purchases and 5 sales. Filers took a median of 4 days from execution to disclosure, and the most recent trade was executed Jun 17 and filed Jun 22. The most active filer was Luke Evnin with 2 filings. Data as of Nov 7 2026.

Add to watchlist
Filings, ttm
5
0 buys · 5 sells
Traders, ttm
3
3 insiders
Volume, ttmiDollar value disclosed in the window
$849K
estimated for Congress, as filed for insiders
Median delay
4d
execution to disclosure
Last traded
Jun 17
Filed Jun 22
ADViAverage daily dollar volume
$290K
market data
Share price · 12M
$0.40 (-65.4%)
$1.16$0.73$0.31Nov 10 2025Mar 25Aug 5

Adjusted for splits and dividends.

Volume by month
$1.2M$618K$0Dec 2024Jun 2025Dec 2025Jun 2026May 2025 · buys $435KOct 2025 · sells $1.0MNov 2025 · sells $1.2MMay 2026 · sells $585KJun 2026 · sells $264K
Buys $435K Sells $3.1M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed · past 24 months
LE Luke Evnin Director 4 filings · 0 buys, 4 sales ML MPM BioVentures 2014 LLC 10% owner 2 filings · 0 buys, 2 sales RP Ra Capital Management, L.P. Director 2 filings · 0 buys, 2 sales PK Peter Kolchinsky Director 1 filing · 0 buys, 1 sale ML MPM Asset Management Investors BV2014 LLC 10% owner 1 filing · 0 buys, 1 sale ML MPM BioImpact LLC Other 1 filing · 0 buys, 1 sale ML Mpm Oncology Innovations Fund Lp 10% owner 1 filing · 0 buys, 1 sale RP RA Capital Nexus Fund II, L.P. Director 1 filing · 1 buy, 0 sales
All 9 filers UP UBS Oncology Impact Fund L.P. 10% owner 1 filing · 0 buys, 1 sale
Recent filings
Ra Capital Management, L.P.SALE 10% owner $136K
389,216 sh × $0.35
Exec Jun 17
Filed Jun 22 · 5:30 PM ET Peter KolchinskySALE 10% owner $128K
345,235 sh × $0.37
Exec Jun 9
Filed Jun 11 · 5:30 PM ET Ra Capital Management, L.P.SALE 10% owner $250K
351,514 sh × $0.71
Exec May 8
Filed May 12 · 5:30 PM ET Luke EvninSALE Director $214K
305,741 sh × $0.70
Exec May 8
Filed May 12 · 5:30 PM ET Luke EvninSALE Director $121K
168,262 sh × $0.72
Exec Apr 30
Filed May 4 · 5:30 PM ET MPM BioImpact LLCSALE 10% owner $171K
140,488 sh × $1.22
Exec Nov 4 2025
Filed Nov 6 2025 · 5:30 PM ET MPM BioVentures 2014 LLCSALE 10% owner $171K
140,488 sh × $1.22
Exec Nov 4 2025
Filed Nov 6 2025 · 5:30 PM ET Luke EvninSALE Director $110K
90,164 sh × $1.22
Exec Nov 4 2025
Filed Nov 6 2025 · 5:30 PM ET Mpm Oncology Innovations Fund LpSALE 10% owner $392K
295,043 sh across 3 lots
Exec Oct 30 2025
Filed Nov 3 2025 · 5:30 PM ET MPM Asset Management Investors BV2014 LLCSALE 10% owner $392K
295,043 sh across 3 lots
Exec Oct 30 2025
Filed Nov 3 2025 · 5:30 PM ET UBS Oncology Impact Fund L.P.SALE 10% owner $446K
276,017 sh across 3 lots
Exec Oct 27 2025
Filed Oct 29 2025 · 5:30 PM ET MPM BioVentures 2014 LLCSALE 10% owner $446K
276,017 sh across 3 lots
Exec Oct 27 2025
Filed Oct 29 2025 · 5:30 PM ET Luke EvninSALE Director $134K
86,154 sh × $1.55
Exec Oct 29 2025
Filed Oct 29 2025 · 5:30 PM ET RA Capital Nexus Fund II, L.P.PURCHASE Director $435K
483,452 sh across 2 lots
Exec May 12 2025
Filed May 14 2025 · 5:30 PM ET